Elios Vision

Elios Vision is a clinical-stage medical device company pioneering a novel, laser-based approach to glaucoma treatment. Its ELIOS system is a minimally invasive glaucoma surgery (MIGS) device that uses a cold excimer laser to precisely ablate tissue and restore the eye's natural drainage pathway, with the key advantage of being performed simultaneously with cataract surgery. The company is targeting the large and growing global market for glaucoma interventions, aiming to offer a safer and more effective alternative to traditional surgeries and standalone MIGS devices. As a private firm, Elios is likely advancing through clinical validation and regulatory pathways towards commercialization.

Proprietary excimer laser system (308nm) for precise photoablation of the trabecular meshwork to restore natural aqueous humor drainage in the eye.

Elios competes in the crowded MIGS market against established players like Alcon (iStent, Hydrus), Glaukos (iStent inject, iPRIME), and New World Medical (Ahmed Valve). Its key differentiator is the use of a cold excimer laser, contrasting with mechanical stents, tissue-cutting devices, or implants from competitors. Success depends on proving clinical superiority, ease of use, and cost-effectiveness.